Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 31.1% from a year ago
Cash & equivalents stood at $20.96M at the end of Q1 FY2026, down 31.1% from a year earlier and down 21.5% from the prior quarter. Over 3 fiscal years it compounded at -36.1% a year.
Context
- Cash & equivalents amounted to 19.8% of total assets at the end of Q1 FY2026, up 3.9 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -31.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 26.7M USD
- Year-over-year change
- -33.6%
- 4-year CAGR
- -36.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.7M | -33.6% |
| FY2024 | 2024-12-31 | 40.24M | -24.8% |
| FY2023 | 2023-12-31 | 53.5M | -47.8% |
| FY2022 | 2022-12-31 | 102.53M | -36.3% |
| FY2021 | 2021-12-31 | 160.92M | — |
Cash & Equivalents vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -31.1% is the 7th highest of 9, against a peer median of +2.4%.
- Cash & equivalents amounts to 19.8% of total assets for ARTV, versus a peer median of 47.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $99.37M USD | +28.7% | -16.4% | 69.1% | |
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
| Mar 2026 | $73.68M USD | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $63.17M USD | +50.0% | +18.3% | 63.6% | |
| Dec 2025 | $38.35M USD | -51.0% | -21.4% | 68.4% | |
| Mar 2026 | $32.28M USD | +56.6% | -30.5% | 18.1% | |
| Mar 2026 | $31.93M USD | -23.8% | -5.8% | 12.6% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M USD | -31.1% | -36.1% | 19.8% |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Peer median (excluding ARTV) | — | +2.4% | -3.2% | 47.1% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 160.92M | 102.53M | 53.5M | 40.24M | 26.7M |
| Short-term Investments | 0 | 0 | 23.47M | 145.19M | 81.31M |
| Net Receivables | 468K | 525K | 1.76M | 146K | 767K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.62M | 1.09M | 3.06M | 3.89M |
| Total Current Assets | 162.29M | 104.68M | 79.82M | 188.63M | 112.67M |
| Property, Plant & Equipment (Net) | 4.08M | 27.62M | 24.64M | 20.43M | 17.36M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 245K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.56M | 517K | 650K | 525K | 919K |
| Total Non-current Assets | 7.64M | 28.38M | 25.29M | 20.95M | 18.27M |
| Total Assets | 169.93M | 133.05M | 105.11M | 209.58M | 130.94M |
| Account Payables | 1.44M | 1.1M | 614K | 1.12M | 355K |
| Short-term Debt | 0 | 0 | 0 | 0 | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.3M | 10.89M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 2.1M |
| Total Current Liabilities | 19.31M | 25.63M | 12.23M | 12.25M | 13.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.88M |
| Deferred Tax Liabilities | 216.41M | 216.41M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 21.68M | 15.64M | 0 | 0 | 0 |
| Other Non-current Liabilities | 81K | 115K | 241.59M | 73K | 0 |
| Total Non-current Liabilities | 239.48M | 248.13M | 254.9M | 10.69M | 7.88M |
| Total Liabilities | 258.78M | 273.75M | 267.13M | 22.94M | 20.97M |
| Common Stock | 0 | 0 | 0 | 3K | 3K |
| Retained Earnings | (93.8M) | (152.59M) | (181.31M) | (246.68M) | (330.55M) |
| Accumulated OCI | 0 | 0 | 308K | (129K) | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (88.86M) | (140.7M) | (162.02M) | 186.64M | 109.97M |
| Total Debt | 1.74M | 19.45M | 16.91M | 14.35M | 10.94M |
| Net Debt | (159.18M) | (83.08M) | (36.59M) | (25.88M) | (15.76M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.